Leap Therapeutics Statistics Share Statistics Leap Therapeutics has 41.44M
shares outstanding. The number of shares has increased by 8.15%
in one year.
Shares Outstanding 41.44M Shares Change (YoY) 8.15% Shares Change (QoQ) 0% Owned by Institutions (%) 33.34% Shares Floating 34.67M Failed to Deliver (FTD) Shares 4,928 FTD / Avg. Volume 0.35%
Short Selling Information The latest short interest is 1.42M, so 3.42% of the outstanding
shares have been sold short.
Short Interest 1.42M Short % of Shares Out 3.42% Short % of Float 4.02% Short Ratio (days to cover) 2.44
Valuation Ratios The PE ratio is -1.6 and the forward
PE ratio is -1.38.
Leap Therapeutics's PEG ratio is
0.03.
PE Ratio -1.6 Forward PE -1.38 PS Ratio 0 Forward PS 3.7 PB Ratio 3.09 P/FCF Ratio -1.79 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Leap Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.41,
with a Debt / Equity ratio of 0.01.
Current Ratio 3.41 Quick Ratio 3.41 Debt / Equity 0.01 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.3M Employee Count 52 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 585K Effective Tax Rate -0.87%
Stock Price Statistics The stock price has increased by -79.3% in the
last 52 weeks. The beta is -0.06, so Leap Therapeutics's
price volatility has been lower than the market average.
Beta -0.06 52-Week Price Change -79.3% 50-Day Moving Average 0.33 200-Day Moving Average 0.71 Relative Strength Index (RSI) 62.94 Average Volume (20 Days) 1,397,946
Income Statement
Revenue n/a Gross Profit -5K Operating Income -70.06M Net Income -67.56M EBITDA -66.97M EBIT -66.97M Earnings Per Share (EPS) -1.81
Full Income Statement Balance Sheet The company has 47.25M in cash and 266K in
debt, giving a net cash position of 46.98M.
Cash & Cash Equivalents 47.25M Total Debt 266K Net Cash 46.98M Retained Earnings -467.37M Total Assets 34.88M Working Capital 19.83M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -60.3M
and capital expenditures 0, giving a free cash flow of -60.3M.
Operating Cash Flow -60.3M Capital Expenditures n/a Free Cash Flow -60.3M FCF Per Share -1.61
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields LPTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for LPTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 21, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Jun 21, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -24.79 Piotroski F-Score 2
